Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
N/A
N/A
Both
Invasive Cancer, Sarcoma, Hematologic Cancer
Trial Information
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Information about patients/participants' diseases and previous and future treatments and
outcomes will be recorded from medical records. A sample of tumor tissue that was already
collected and stored at MD Anderson or another institution will be collected. Blood (about 4
teaspoons) will be drawn so that researchers have a sample of normal cells to use for
comparison to cancer cells, a saliva sample or a cheek cell sample may be collected instead
of the blood sample.
The MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized
Cancer Therapy (IPCT) is committed to implementing personalized cancer therapy for all
patients coming to MD Anderson, transforming cancer patient management and improving
outcomes by making this approach the new standard of care. The ultimate goal is to perform
in-depth molecular characterization of all tumors, in order to tailor therapies offered and
identify best standard of care and clinical trial options.
Inclusion Criteria:
1. Patients must have histologically or cytologically documented invasive cancer,
suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign
tumors may also be consented at the discretion of the attending physician if
molecular profiling is felt to have potential clinical implications.
2. Patients must have the ability to understand and the willingness to sign a written
informed consent document.
3. Patients may be consented without confirming the amount and quality of archival
diagnostic or residual tissue available. However, research testing will only be
performed on patients who have sufficient archived diagnostic tissue or residual
tissue banked in one of the authorized tissue banks at MD Anderson available to
proceed with testing. The extent of testing may be modified based on amount of
tissue available. If a new biopsy is being ordered for clinical care or another
research study, or an operation is being performed testing can be ordered on that
sample.
Exclusion Criteria:
None.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Database of Somatic Mutations and Clinical Characteristics
Outcome Description:
Collection and storage of tumor tissue specimens, blood and/or saliva samples of patients with cancer for somatic mutation analysis for assessing patients that may be eligible for new targeted therapy trials.
Outcome Time Frame:
20 years
Safety Issue:
No
Principal Investigator
Funda Meric-Bernstam, MD
Investigator Role:
Study Chair
Investigator Affiliation:
UT MD Anderson Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
PA11-0852
NCT ID:
NCT01772771
Start Date:
March 2012
Completion Date:
Related Keywords:
- Invasive Cancer
- Sarcoma
- Hematologic Cancer
- Cancer
- Molecular testing
- Personalized Cancer Therapy Program
- Bladder
- Bone
- Breast
- Cytology
- Endocrine
- Gynecology
- Endocrine - Neoplasia
- genitourinary
- Research Biorepository
- Head and Neck
- Aerodigestive Tract
- Hematopathology
- Human Cancer Genetics
- Kidney
- Leukemia
- Lower Gastrointestinal
- Lymphoma
- Melanoma
- Neurology
- Brain
- Non-Melanoma Skin
- Pancreas
- Pediatrics
- Prostate
- Breast Cancer Patients, Serum
- Plasma
- Soft Tissue Sarcoma
- Thoracic
- Lung
- S.P.O.R.E.
- Upper Gastrointestinal
- Hematologic Neoplasms
- Sarcoma
Name | Location |
|---|---|
| UT MDACC/Regional Cancer Centers | Houston, Texas 77030 |
